Search

Your search keyword '"Maintz C"' showing total 2 results
Start Over Author "Maintz C" Topic multiple myeloma
2 results on '"Maintz C"'

1. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.

Author

Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens MR, Ko Y, Hahn C, Ubelacker R, Kleinschmidt R, and Gieseler F

Subjects
Administration, Oral, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Drug Administration Schedule, Female, Humans, Idarubicin adverse effects, Immunoglobulin A blood, Immunoglobulin G blood, Immunoglobulin Isotypes blood, Immunoglobulin Light Chains blood, Male, Middle Aged, Multiple Myeloma immunology, Multiple Myeloma mortality, Multiple Myeloma pathology, Neoplasm Staging, Survival Rate, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Idarubicin administration & dosage, Multiple Myeloma drug therapy
Abstract

In order to replace the central venous line necessary for continuous infusion of vincristine and doxorubicin with high-dose dexamethasone (VAD) and to avoid hospitalization, we evaluated the efficacy and toxicity of oral idarubicin, vincristine and dexamethasone (VID) in patients with multiple myeloma. Vincristine (1.6 mg/m2, max 2 mg) was given as a bolus injection on day 1. Idarubicin was given in capsules 10 mg/m2/day for days 1-4 with an intraindividual dose escalation, 40 mg dexamethasone were given on days 1-4, 9-12, 17-20. Treatment cycles were repeated every 28 days. At this interim analysis, 53 patients have been entered into the ongoing trial; 46 patients are evaluable for toxicity. The median age was 60 years (interquartile range, 52-65). 46% were primary or secondary refractory, 20% had previously been treated with VAD and 30% had previously untreated disease, 4% had two or more relapses. Four patients died within 2 months from entry and were considered as early deaths (8.7%). 45% of the 42 patients evaluable for efficacy achieved a partial remission and 26% a minor remission. The median reduction of the M-component was 43% (interquartile range, 25-64%). VID is an effective and convenient alternative to VAD even in relapsed or refractory patients.

Published
1997

2. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma

Author

Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens MR, Ko Y, Hahn C, Ubelacker R, Kleinschmidt R, and Frank Gieseler

Subjects
Male, Administration, Oral, Middle Aged, Dexamethasone, Drug Administration Schedule, Immunoglobulin A, Immunoglobulin Isotypes, Survival Rate, Vincristine, Immunoglobulin G, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Immunoglobulin Light Chains, Idarubicin, Multiple Myeloma, Aged, Neoplasm Staging
Abstract

In order to replace the central venous line necessary for continuous infusion of vincristine and doxorubicin with high-dose dexamethasone (VAD) and to avoid hospitalization, we evaluated the efficacy and toxicity of oral idarubicin, vincristine and dexamethasone (VID) in patients with multiple myeloma. Vincristine (1.6 mg/m2, max 2 mg) was given as a bolus injection on day 1. Idarubicin was given in capsules 10 mg/m2/day for days 1-4 with an intraindividual dose escalation, 40 mg dexamethasone were given on days 1-4, 9-12, 17-20. Treatment cycles were repeated every 28 days. At this interim analysis, 53 patients have been entered into the ongoing trial; 46 patients are evaluable for toxicity. The median age was 60 years (interquartile range, 52-65). 46% were primary or secondary refractory, 20% had previously been treated with VAD and 30% had previously untreated disease, 4% had two or more relapses. Four patients died within 2 months from entry and were considered as early deaths (8.7%). 45% of the 42 patients evaluable for efficacy achieved a partial remission and 26% a minor remission. The median reduction of the M-component was 43% (interquartile range, 25-64%). VID is an effective and convenient alternative to VAD even in relapsed or refractory patients.

Catalog

Books, media, physical & digital resources
See catalog results